HC Wainwright reiterated their buy rating on shares of Strata Skin Sciences, Inc. (NASDAQ:SSKN) in a report published on Friday morning. They currently have a $7.00 target price on the medical device company’s stock.
Other equities analysts have also issued reports about the stock. ValuEngine upgraded shares of Strata Skin Sciences from a strong sell rating to a sell rating in a research report on Friday, September 1st. Zacks Investment Research lowered shares of Strata Skin Sciences from a hold rating to a sell rating in a research report on Wednesday, August 16th.
Strata Skin Sciences (NASDAQ SSKN) traded up $0.06 during trading hours on Friday, reaching $1.20. 148,300 shares of the company’s stock were exchanged, compared to its average volume of 119,286. Strata Skin Sciences has a 52-week low of $1.06 and a 52-week high of $5.40. The company has a current ratio of 1.34, a quick ratio of 0.93 and a debt-to-equity ratio of 1.85.
About Strata Skin Sciences
STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.
Receive News & Ratings for Strata Skin Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strata Skin Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.